{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:59:21Z","timestamp":1790621961580,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T00:00:00Z","timestamp":1632009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T00:00:00Z","timestamp":1632009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Moxifloxacin is a fourth-generation fluoroquinolone used as a second-line treatment for multiple bacterial infections. Uveitis has been described as an adverse effect related to this medication. Although several case reports have been published describing uveitis and bilateral acute iris transillumination syndrome related to moxifloxacin, we present a unique case of a patient with severe sequelae associated with bilateral acute iris transillumination syndrome secondary to the use of oral moxifloxacin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 45-year-old Colombian hispanic female presented bilateral conjunctival hyperemia, decreased visual acuity, blurred vision, photophobia, and ocular pain after 15\u00a0days of treatment with systemic moxifloxacin for an upper tract respiratory infection. The patient presented unilateral anterior chamber pigment dispersion, mydriatic and nonreactive pupils, extensive iris transillumination defects, and secondary glaucoma. Blood and aqueous humor tests were negative for infectious and autoimmune diseases. Moxifloxacin-induced bilateral acute iris transillumination syndrome was diagnosed. Permanent sequelae such as ocular pain, photophobia, and focus difficulty secondary to severe bilateral iridian atrophy and inability of synkinetic reflex were left. Additionally, glaucoma was diagnosed, and Ahmed valve implantation was required.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We should be aware of the possible association between moxifloxacin and bilateral acute iris transillumination syndrome. A detailed anamnesis, adequate examination, and laboratory tests are necessary to reach an early diagnosis and treatment to avoid unnecessary therapies. Larger studies should be carried out to understand the pathophysiology, diagnosis, management, and sequelae of the disease.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13256-021-03075-y","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T23:05:17Z","timestamp":1632006317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Severe sequelae in bilateral acute iris transillumination syndrome secondary to the use of oral moxifloxacin: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Nicol\u00e1s","family":"Rivera-Valdivia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Arteaga-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Reyes-Guanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Neira-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-1989","authenticated-orcid":false,"given":"Alejandra","family":"de-la-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,19]]},"reference":[{"key":"3075_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1021\/bi5000564","volume":"53","author":"KJ Aldred","year":"2014","unstructured":"Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53:1565\u201374.","journal-title":"Biochemistry"},{"key":"3075_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/molecules21040268","volume":"21","author":"A Naeem","year":"2016","unstructured":"Naeem A, Badshah SL, Muska M, Ahmad N, Khan K. The current case of quinolones: synthetic approaches and antibacterial activity. Molecules. 2016;21:268.","journal-title":"Molecules"},{"key":"3075_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1751-7915.2008.00063.x","volume":"2","author":"A F\u00e0brega","year":"2009","unstructured":"F\u00e0brega A, Madurga S, Giralt E, Vila J. Mechanism of action of and resistance to quinolones. Microb Biotechnol. 2009;2:40\u201361.","journal-title":"Microb Biotechnol"},{"key":"3075_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jamaophthalmol.2014.3598","volume":"133","author":"B Eadie","year":"2015","unstructured":"Eadie B, Etminan M, Mikelberg FS. Risk for uveitis with oral moxifloxacin: a comparative safety study. JAMA Ophthalmol. 2015;133:81\u20134.","journal-title":"JAMA Ophthalmol"},{"key":"3075_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/11634300-000000000-00000","volume":"12","author":"PM Tulkens","year":"2012","unstructured":"Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety. Drugs R&D. 2012;12:71\u2013100.","journal-title":"Drugs R&D"},{"key":"3075_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3109\/15569527.2011.617024","volume":"31","author":"DM Hinkle","year":"2012","unstructured":"Hinkle DM, Dacey MS, Mandelcorn E, Kalyani P, Mauro J, Bates JH, et\u00a0al. Bilateral uveitis associated with fluoroquinolone therapy. Cutan Ocul Toxicol. 2012;31:111\u20136.","journal-title":"Cutan Ocul Toxicol"},{"key":"3075_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jfo.2012.07.002","volume":"36","author":"A Duncombe","year":"2013","unstructured":"Duncombe A, Gueudry J, Massy N, Chapuzet C, Gueit I, Muraine M. Severe pseudouveitis associated with moxifloxacin therapy. J Fr Ophtalmol. 2013;36:146\u201350.","journal-title":"J Fr Ophtalmol"},{"key":"3075_CR8","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1038\/eye.2009.234","volume":"23","author":"M Wefers Bettink-Remeijer","year":"2009","unstructured":"Wefers Bettink-Remeijer M, Brouwers K, van Langenhove L, De Waard PWT, Missotten TO, Martinez Ciriano JP, et\u00a0al. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond). 2009;23:2260\u20132.","journal-title":"Eye (Lond)"},{"key":"3075_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2174\/1874364101711010107","volume":"11","author":"DM Hinkle","year":"2017","unstructured":"Hinkle DM, Kruh-Garcia NA, Kruh JN, Broccardo C, Doctor P, Foster CS. Moxifloxacin concentration and proteomic analysis of aqueous humor in human uveitis associated with oral moxifloxacin therapy. Open Ophthalmol J. 2017;11:107\u201316.","journal-title":"Open Ophthalmol J"},{"key":"3075_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4321\/S0365-66912004000700011","volume":"79","author":"R Bringas Calvo","year":"2004","unstructured":"Bringas Calvo R, Iglesias CD. Acute and bilateral uveitis secondary to moxifloxacin. Arch Soc Esp Oftalmol. 2004;79:357\u20139.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"3075_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.oftal.2017.12.018","volume":"93","author":"P Plaza-Ramos","year":"2018","unstructured":"Plaza-Ramos P, Heras-Mulero H, Fanlo P, Zubicoa A. Bilateral acute iris transillumination syndrome. A case report. Arch Soc Esp Oftalmol (English Edition). 2018;93:447\u201350.","journal-title":"Arch Soc Esp Oftalmol (English Edition)"},{"key":"3075_CR12","unstructured":"Rangel CM, Parra MM, Frederick G, Tello A, Var\u00f3n CL. An unusual case of bilateral anterior uveitis related to moxifloxacin: the first report in Latin America. GMS Ophthalmol Cases [Internet]. 2017 [cited 2020 Sep 7];7. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5506693\/."},{"key":"3075_CR13","first-page":"321","volume":"71","author":"A Broens","year":"2016","unstructured":"Broens A, Collignon N. Moxiflaxin and iris transillumination. Rev Med Liege. 2016;71:321\u20133.","journal-title":"Rev Med Liege"},{"key":"3075_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1869-5760-3-10","volume":"3","author":"RM Knape","year":"2013","unstructured":"Knape RM, Sayyad FE, Davis JL. Moxifloxacin and bilateral acute iris transillumination. J Ophthalmic Inflamm Infect. 2013;3:10.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"3075_CR15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.6061\/clinics\/2013(07)02","volume":"68","author":"do Nascimento HM, de Sousa JM, de Queiroz Campos MS, Belfort R","year":"2013","unstructured":"do Nascimento HM, de Sousa JM, de Queiroz Campos MS, Belfort R. Acute iris depigmentation following systemic moxifloxacin. Clinics (Sao Paulo). 2013;68:899\u2013900.","journal-title":"Clinics (Sao Paulo)"},{"key":"3075_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3109\/09273948.2012.670359","volume":"20","author":"RG Morshedi","year":"2012","unstructured":"Morshedi RG, Bettis DI, Moshirfar M, Vitale AT. Bilateral acute iris transillumination following systemic moxifloxacin for respiratory illness: report of two cases and review of the literature. Ocul Immunol Inflamm. 2012;20:266\u201372.","journal-title":"Ocul Immunol Inflamm"},{"key":"3075_CR17","doi-asserted-by":"crossref","unstructured":"Willermain F, Deflorenne C, Bouffioux C, Janssens X, Koch P, Caspers L. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond). 2010;24:1419; author reply 1419\u201320.","DOI":"10.1038\/eye.2010.19"},{"key":"3075_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11010-014-2297-7","volume":"401","author":"A Beberok","year":"2015","unstructured":"Beberok A, Wrze\u015bniok D, Otr\u0119ba M, Mili\u0144ski M, Rok J, Buszman E. Effect of norfloxacin and moxifloxacin on melanin synthesis and antioxidant enzymes activity in normal human melanocytes. Mol Cell Biochem. 2015;401:107\u201314.","journal-title":"Mol Cell Biochem"},{"key":"3075_CR19","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2147\/OPTH.S167449","volume":"13","author":"JM Perone","year":"2019","unstructured":"Perone JM, Chaussard D, Hayek G. Bilateral acute iris transillumination (BAIT) syndrome: literature review. Clin Ophthalmol. 2019;13:935\u201343.","journal-title":"Clin Ophthalmol"},{"key":"3075_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jfo.2017.01.018","volume":"40","author":"JM Perone","year":"2017","unstructured":"Perone JM, Reynders S, Sujet-Perone N, Yahia R, Neiter E, Krawczyk P, et\u00a0al. Bilateral acute iris transillumination syndrome: case report. J Fr Ophtalmol. 2017;40:713\u20136.","journal-title":"J Fr Ophtalmol"},{"key":"3075_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12886-016-0369-z","volume":"16","author":"A Chronopoulos","year":"2016","unstructured":"Chronopoulos A, Roquelaure D, Souteyrand G, Seebach JD, Schutz JS, Thumann G. Aqueous humor polymerase chain reaction in uveitis\u2014utility and safety. BMC Ophthalmol. 2016;16:189.","journal-title":"BMC Ophthalmol"},{"key":"3075_CR22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0974-9233.58416","volume":"16","author":"CP Herbort","year":"2009","unstructured":"Herbort CP. Appraisal, work-up and diagnosis of anterior uveitis: a practical approach. Middle East Afr J Ophthalmol. 2009;16:159.","journal-title":"Middle East Afr J Ophthalmol"},{"key":"3075_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1590\/S0004-27492013000100012","volume":"76","author":"Maestrini HA, Maestrini AA, Machado de DO, Santos DVV, de Almeida HG","year":"2013","unstructured":"Maestrini HA, Maestrini AA, Machado de DO, Santos DVV, de Almeida HG. Bilateral acute depigmentation of the iris (BADI): first reported case in Brazil. Arq Bras Oftalmol. 2013;76:42\u20134.","journal-title":"Arq Bras Oftalmol"},{"key":"3075_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1076\/ocii.9.3.169.3964","volume":"9","author":"S Velilla","year":"2001","unstructured":"Velilla S, Dios E, Herreras JM, Calonge M. Fuchs\u2019 heterochromic iridocyclitis: a review of 26 cases. Ocul Immunol Inflamm. 2001;9:169\u201375.","journal-title":"Ocul Immunol Inflamm"},{"key":"3075_CR25","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s10792-018-0938-7","volume":"39","author":"G Scuderi","year":"2019","unstructured":"Scuderi G, Contestabile MT, Scuderi L, Librando A, Fenicia V, Rahimi S. Pigment dispersion syndrome and pigmentary glaucoma: a review and update. Int Ophthalmol. 2019;39:1651\u201362.","journal-title":"Int Ophthalmol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-03075-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T15:18:06Z","timestamp":1725808686000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-03075-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,19]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3075"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-03075-y","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,19]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"462"}}